Brief: Compugen Ltd Announces Milestone Payment From Astrazeneca Triggered By First Patient Dosed With Tigit Bispecific Derived From COM902
04/10/2021 12:18
Oct 4 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN ANNOUNCES MILESTONE PAYMENT FROM ASTRAZENECA
TRIGGERED
BY FIRST PATIENT DOSED WITH TIGIT BISPECIFIC DERIVED FROM COM902
* COMPUGEN - FIRST PATIENT DOSED IN PHASE 1/2 STUDY OF
AZD2936,
ENTITLING CO TO RECEIVE $6 MILLION PAYMENT FROM ASTRAZENECA AS
PART OF LICENSE AGREEMENT
Source text for Eikon: ID:nPnbpcX9Ta
Further company coverage: CGEN.TA
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025